問卷

TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Endocrinology

更新時間:2023-09-19

歐昱侖
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

3Cases

2024-01-16 - 2026-06-30

Phase III

Active
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes
  • Condition/Disease

    Type 2 diabetes

  • Test Drug

    CagriSemaTirzepatide

Participate Sites
7Sites

Recruiting7Sites

2020-10-01 - 2024-12-31

Phase III

Completed
Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease
  • Condition/Disease

    Diabetes Mellitus, Type 2/Peripheral Arterial Disease

  • Test Drug

    Semaglutide 1.34 mg/ml / placebo

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting1Sites

Terminated4Sites

2024-11-05 - 2027-02-02

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites